| abstract |
Among other things, the invention provides methods and compositions for the treatment of complement-mediated diseases. In some embodiments, the present invention provides a recombinant human C1 esterase inhibitor protein having a half-life similar to or longer than that of a natural plasma-derived human C1 esterase inhibitor and a method for preparing the same. In some embodiments, the invention provides methods of administering to an individual having or susceptible to a complement-mediated disease an effective amount of recombinant human C1 esterase inhibitor protein such that at least one of the complement-mediated diseases Symptoms or features are prevented and/or reduced in intensity, severity, or frequency. |